Summary & Overview
HCPCS J1568: Intravenous Immune Globulin (Octagam), 500 mg
HCPCS Level II code J1568 represents intravenous immune globulin, Octagam, in a liquid (non-lyophilized) formulation, billed per 500 mg. This code identifies a high-cost biologic therapy used for immune modulation and replacement across multiple clinical indications, and it is important for national billing, utilization tracking, and payer policy around specialty infusion medications. Payers commonly managing coverage for this product nationally include Aetna, Blue Cross Blue Shield, Cigna, UnitedHealthcare, and Medicare.
Readers will find benchmarks for unit-based billing and utilization patterns, an overview of payer coverage frameworks and prior authorization trends, and the clinical context for Octagam administration (indication types and infusion settings). The publication summarizes common billing considerations, typical sites of service for intravenous infusion, and how unit-based HCPCS coding translates to dosing and charge calculation. Data not available in the input where specific utilization or payer policy details are required.
Billing Code Overview
HCPCS Level II code J1568 describes an intravenous immune globulin (Octagam) preparation supplied as a non-lyophilized (liquid) formulation, billed per 500 mg unit. This product is an immune globulin used for passive immunotherapy and immune modulation in clinical indications that require intravenous immunoglobulin.
-
Service type: Parenteral infusion medication (intravenous therapeutic drug)
-
Typical site of service: Hospital outpatient infusion center, ambulatory infusion clinic, or physician office infusion suite where intravenous infusions are administered
Clinical & Coding Specifications
Clinical Context
A typical patient receiving J1568 is an adult or pediatric patient requiring intravenous immune globulin (IVIG) replacement or immunomodulatory therapy, administered as Octagam 500 mg vial(s) in liquid form. A realistic scenario: a 45-year-old female with common variable immunodeficiency presents to an outpatient infusion center for scheduled IVIG therapy every 3–4 weeks. Pre-infusion nursing assessment includes verification of diagnosis and orders, baseline vital signs, review of prior infusion tolerance, and assessment for active infection or contraindications. The pharmacy prepares weight‑based IVIG dosing using J1568 vials, verifies lot numbers, and labels infusion bags. During infusion, a registered nurse initiates IV access, programs the infusion pump for a gradual titration per institutional protocol, monitors for infusion reactions (headache, flushing, hypotension, anaphylaxis), and documents vital signs at protocol intervals. Post‑infusion observation captures adverse events and disposition. Billing uses J1568 to report each 500 mg vial of Octagam administered; total billed units reflect the total milligrams infused divided by 500 mg. Typical sites of service include outpatient infusion centers, hospital outpatient departments, skilled nursing facilities, and occasionally inpatient settings for acute immune-mediated conditions.
Coding Specifications
| Modifier | Description | When to Use |
|---|